scholarly journals Could it have been better? A patient with peripartum cardiomyopathy treated with conventional therapy

2012 ◽  
Vol 69 (6) ◽  
pp. 526-530
Author(s):  
Branislava Ivanovic ◽  
Marijana Tadic ◽  
Ruzica Maksimovic ◽  
Bojana Orbovic

Introduction. Peripartum cardiomyopathy is a life threatening condition of unknown cause that occurs in previously healthy women. It is characterized by symptoms of heart failure due to left ventricular dysfunction that occurs in the last month of pregnancy or the first five months after delivery. Case report. We presented woman who underwent caesarean section due to preeclampsia. Two weeks after delivery first signs of heart failure appeared and only after six weeks following the onset of symptoms peripartal cardiomyopathy was recognized. A conventional treatment with diuretics, ACE inhibitor and beta blocker along with anticoagulant therapy was applied, which resulted in a complete recovery of the left ventricular function four months after. Conclusion. Timely detection and initiation of treatment are an important precondition for the complete or partial recovery.

2021 ◽  
Vol 2 (1) ◽  
pp. 46-49
Author(s):  
Monika Sitio ◽  
Cholid Tri Tjahjono ◽  
Heny Martini ◽  
Novi Kurnianingsih

Peripartum cardiomyopathy (PPCM) is a diagnosis of exclusion, where patients present with heart failure (HF) secondary to left ventricular (LV) systolic dysfunction without any other cause of HF identified in the last month of pregnancy or within first five months after delivery, abortion, or miscarriage. PPCM is a life-threatening condition which frequently under diagnosed and inadequately treated, whereas the morbidity and mortality rate ranges between 7% and 50%. Early diagnosis is important to decrease morbidity and mortality. Therefore, it is necessary to report the case related to this condition. A 34-year-old woman was referred to RSSA with worsening shortness of breath (SOB). She has given birth about 2.5 months prior to admission. History taking and supporting findings form this case were supported to diagnosis of PPCM. She was treated with diuretic, aldosterone antagonist, ACE-I, beta blocker, anticoagulant, and bromocriptine. The symptoms were improved in the following days. She was discharged with better condition and educated to comply with medication.


ESC CardioMed ◽  
2018 ◽  
pp. 1549-1553
Author(s):  
Karen Sliwa ◽  
Denise Hilfiker-Kleiner

Pregnancy-related heart disease is increasing worldwide and peripartum cardiomyopathy (PPCM) is an important contributor to early (<42 days postpartum) and late (up to 1 year postpartum) maternal death. PPCM is a potentially life-threatening condition presenting with heart failure secondary to left ventricular dysfunction towards the end of pregnancy, or in the months following delivery, where no other cause of heart failure is identified. It is a diagnosis of exclusion. Incidence and prognosis varies according to geography and is likely due to multiple factors including also inherited or acquired cardiomyopathy-associated mutations. It seems that PPCM also shares common pathological pathways. For example, a ‘multiple-hit’ model including systemic angiogenic imbalance that derives from the oxidative stress-cathepsin D-16 kDa prolactin cascade and additional antiangiogenic factors plays a key role in the development of PPCM in experimental models and in humans suggests that a therapeutic approach involving blockade of this pathway with bromocriptine may be a novel disease-specific approach. Despite ongoing research, numerous uncertainties regarding the incidence, pathophysiology, treatment, and prognosis of PPCM patients remain, indicating the need for further investigation. The ongoing global registry on PPCM, under the umbrella of the EuroObservational research programme, has provided novel information.


2012 ◽  
Vol 19 (3) ◽  
pp. 224-227
Author(s):  
Andrius Macas ◽  
Kęstutis Rimaitis ◽  
Giedrė Bakšytė ◽  
Laura Šilinskytė

Peripartum cardiomyopathy is an unusual and uncommon form of dilat­ ed cardiomyopathy that is often fatal to young women, the cause of which is unknown. Diagnostics is difficult and requires vigilance. The treatment does not differ from other forms of heart failure. Fetal outcome, however, is quite good. Maternal outcomes depend on 2–6 months recovery of the left ventricular function. We describe a previously asymptomatic patient who presented with pulmonary edema one day after caesarean section. In this case the solution was favorable to the patient. Complete recovery of the left ventricular function happened earlier than indicated in litera­ ture.


2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
Z Y Vasquez-Ortiz ◽  
R Gonzalez-Varela ◽  
J Navarrete Garcia ◽  
P Hernandez-Reyes ◽  
J Oseguera Moguel

Abstract Introduction Peripartum cardiomyopathy (MPP) is a type of cardiomyopathy characterized by heart failure secondary to left ventricular systolic dysfunction during the last month of pregnancy or in the first 5 months of puerperium without other apparent etiology, being a diagnosis of exclusion. The left ventricle is not always dilated, but the fraction of left ventricular ejection is always less than 45%. The natural history and prognosis of the disease is diverse. Ventricular dysfunction is usually transient and normalizes at 3-6 months in up to 60% of cases. Mortality is variable, with reports ranging from 0 to 28%, affecting more certain ethnic groups, in patients with persistent ventricular dysfunction, evidence of the efficacy of a specific treatment beyond optimal medical therapy for heart failure is limited. Clinical case We present the clinical case of a 22-year-old woman, who was referred to the our institute with an acute heart failure syndrome two months after the end of her first pregnancy. On admission to the hospital, dilated cardiomyopathy and intracavitary thrombi were documented by transthoracic echocardiography (TTE) with dilatation and eccentric left ventricular hypertrophy, generalized hypokinesia and mobile thrombi inside, the largest of 34x16mm with severe left ventricular dysfunction 3D LVEF of 28% and global longitudinal strain (GLS) of -5.8%, pulmonary hypertension and right ventricular dysfunction with severe functional tricuspid regurgitation. Other specific etiologies of dilated cardiomyopathy were investigated and discarded, finally establishing the diagnosis of peripartum cardiomyopathy. The support management was carried with inotropic, diuretic, supplemental oxygen and parenteral anticoagulation was initiated, with gradual improvement. Subsequently, optimal medical treatment was started for heart failure, cabergoline and vitamin K antagonist. He was released to his home on II NYHA. Two months later she presented with progressive dyspnea, increased abdominal perimeter. On March 14, 2018, a TTE was performed, with absence of improvement in conventional and advanced ventricular function parameters. Apical thrombi of smaller size compared with previous study, severe left ventricular dysfunction, which worsened with respect to the previous echocardiogram, with 3D LVEF of 25% and GLS 3.7% Discussion We present the case of a woman with MPP, in whom persistent left ventricular dysfunction after 6 months of diagnosis, although cabergoline scheme in addition to optimal medical management for heart failure, with no improvement. In patients who dont present an adequate response to the management, it is necessary to consider enlisting for heart transplantation. Abstract P626 Figure. TTE, severe ventricular dysfunction


2021 ◽  
Author(s):  
Fatima Zahra Merzouk ◽  
Sara Oualim ◽  
Mohammed Sabry

Peripartum cardiomyopathy (PPCM) is the most common cardiomyopathy in pregnancy. It is potentially life-threatening. It is, diagnosed in women without a history of heart disease 1 month before delivery or within 5 months. It is marked by heart failure and left ventricular dyshfunction. The evolution is favorable. LV function improves within 6 months in the majority of patients, but long-lasting mortality and morbidity are not infrequent. Recent work suggests the critical toxic role for late-gestational hormones on the maternal vasculature and the genetic underpinnings of PPCM. Complications include different types of supraventricular and ventricular arrhythmias, heart failure and ischemic stroke. The brain natriuretic peptide (BNP) can be used to risk stratify women for adverse events. Management of peripartum cardiomyopathy is based on treatment of heart failure. The addition of bromocriptine seemed to improve LVEF. Close monitoring of pregnant women with cardiomyopathy by multidisciplinary team is recommended.


2019 ◽  
Vol 116 (3) ◽  
pp. 520-531 ◽  
Author(s):  
Melanie Ricke-Hoch ◽  
Tobias J Pfeffer ◽  
Denise Hilfiker-Kleiner

Abstract Peripartum cardiomyopathy (PPCM) is a life-threatening cardiomyopathy characterized by acute or slow progression of left ventricular (LV) systolic dysfunction (LV ejection fraction of &lt;45%) late in pregnancy, during delivery, or in the first postpartum months, in women with no other identifiable causes of heart failure. PPCM patients display variable phenotypes and risk factor profiles, pointing to involvement of multiple mechanisms in the pathogenesis of the disease. The higher risk for PPCM in women with African ancestry, the prevalence of gene variants associated with cardiomyopathies, and the high variability in onset and disease progression in PPCM patients also indicate multiple mechanisms at work. Experimental data have shown that different factors can induce and drive PPCM, including inflammation and immunity, pregnancy hormone impairment, catecholamine stress, defective cAMP-PKA, and G-protein-coupled-receptor signalling, and genetic variants. However, several of these mechanisms may merge into a common major pathway, which includes unbalanced oxidative stress and the cleavage of the nursing hormone prolactin (PRL) into an angiostatic, pro-apoptotic, and pro-inflammatory 16 kDa-PRL fragment, resulting in subsequent vascular damage and heart failure. Based on this common pathway, potential disease-specific biomarkers and therapies have emerged. Despite commonalities, the variation in aetiology and mechanisms poses challenges for the diagnosis, treatment, and management of the disease. This review summarizes current knowledge on the clinical presentation of PPCM in the context of recent experimental research. It discusses the challenge to develop disease-specific biomarkers in the context of rapid changing physiology in the peripartum phase, and outlines possible future treatment and management strategies for PPCM patients.


Author(s):  
Karen Sliwa ◽  
Denise Hilfiker-Kleiner

Pregnancy-related heart disease is increasing worldwide and peripartum cardiomyopathy (PPCM) is an important contributor to early (<42 days postpartum) and late (up to 1 year postpartum) maternal death. PPCM is an idiopathic form of cardiomyopathy, presenting with heart failure secondary to left ventricular dysfunction towards the end of pregnancy, or in the months following delivery, where no other cause of heart failure is identified. It is a diagnosis of exclusion. Incidence and prognosis varies according to geography and is likely due to multiple factors. The recent specific pathophysiological hypothesis which states that the oxidative stress–cathepsin D-16 kDa prolactin cascade plays a key role in the development of PPCM in experimental models and in humans suggests that a therapeutic approach involving blockade of this pathway with bromocriptine may be a novel disease-specific approach. Despite ongoing research, numerous uncertainties regarding the incidence, pathophysiology, treatment, and prognosis of PPCM patients remain, indicating the need for further investigation. The establishment of the international registry on PPCM, under the umbrella of the EuroObservational research programme, will provide novel information and address many uncertainties.


Author(s):  
Muhammad Mubin ◽  
Adeel Riaz ◽  
Muhammad Mubbashir Sheikh ◽  
Hafiz Muhammad Umair ◽  
Muhammad Shah Nawaz ul Rehman ◽  
...  

Peripartum Cardiomyopathy (PPCM) is a pregnancy-associated cardiac disorder, which is potentially lifethreatening and manifests as left ventricular dysfunction and heart failure. The disease is rather rare and in most patients cardiac function recovers well, but long-term morbidity and mortality are not uncommon. Research studies suggest pregnancy-induced hormones and mediators, which cause vascular dysfunction, trigger that peri-partum cardiomyopathy. Genetic factors are also thought to play a role in pathophysiology. Management of peri-partum cardiomyopathy is same as cardiac failure and drugs against mediators like prolactin are under investigations, but no proven disease-specific therapies had been reported. We report a case of 35-year-old female who, instead of heart failure, had hypertension as sole presenting complaint of PPCM. Complications associated with PPCM are severe progressive heart failure, arrhythmias, heart block, cardiopulmonary block and thromboembolism. Death could be caused by worsening heart failure, arrhythmias and cardiopulmonary block.


2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Amit Verma ◽  
Shanthi Pinto

AbstractPeripartum cardiomyopathy is idiopathic heart failure occurring in the last month of pregnancy or during the first 5 months postpartum in the absence of determinable heart disease prior to the last month of pregnancy. We aim to raise awareness for this rare and potentially life-threatening disorder amongst all medical professionals involved in the care for pregnant women. A high index of suspicion is required for its diagnosis. Early recognition and treatment in a multidisciplinary team is vital for good prognosis, which depends on reversal of ventricular dysfunction.


Sign in / Sign up

Export Citation Format

Share Document